Indian, UK Authorities Clamp Down On International Medicines Crime

Mumbai, 13 Oct 2018: In an effort to prevent unlicensed medicines entering into the UK market, the Medicines and Healthcare products Regulatory Agency (MHRA) of UK is working closely with law enforcement agencies in India. 

Following a meeting in Delhi on October 12th, MHRA will send intelligence to the Directorate of Revenue Intelligence (DRI), enabling them to target regions suspected of sending unlicensed medicines into the UK.

This is another example of co-ordinated efforts to tackle international medicines crime. The DRI recently seized 350,000 tablets of potent medicines such as Diazepam, Tramadol and Zopiclone destined for UK, European and US markets. Rapid mutual intelligence-sharing will help to combat the illegal cross-border trade in medicines.

The UK and India have a long standing relationship when it comes to collaborating around the issue of medicines. In 2015 both countries signed a memorandum of understanding (MoU), further increasing collaboration in the area of medicines and medical devices and improving public safety.

MHRA’s Head of Enforcement, Alastair Jeffrey said “Our active collaboration with Indian government agencies sends a strong message to criminals; when we work with our global partners we are able to disrupt criminal activity through the identification, arrest and prosecution of offenders wherever they are. We are working tirelessly to identify all those involved in bringing unlicensed medicines into the UK. Our collaborative efforts with key partners like India will help protect the health of UK citizens.”

Additional Director General, Vivek Chaturvedi, said, “Indian Customs is committed to detecting and preventing illegal cross border trade in medicines and psychotropic substances. DRI being the apex intelligence and investigative agency has successfully booked a number of cases, carried out seizures and arrested offenders in recent past. DRI works closely with international law enforcement agencies and regulators and MHRA is an important partner in tackling the menace of trade in illegal medicines. Such collaboration is mutually beneficial to both countries in protecting the health of their citizens and in prosecuting the criminals involved in such offences.” Pharmabiz